Aligos Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 23, 2022, details the results of the Annual Meeting of Stockholders held by Aligos Therapeutics, Inc. on that date. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol "ALGS".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results rather than financial performance.
Material Changes and Voting Results
As of the record date (April 25, 2022), 39,602,857 shares of voting common stock were outstanding. Stockholders voted on two proposals:
- Proposal 1: Election of Class II Directors
- Thomas Woiwode, Ph.D.: 21,310,101 votes For; 4,197,470 votes Withheld; 4,035,425 Broker Non-Votes.
- Leonid Beigelman, Ph.D.: 21,501,183 votes For; 4,006,388 votes Withheld; 4,035,425 Broker Non-Votes.
- K. Peter Hirth, Ph.D.: 21,864,042 votes For; 3,643,529 votes Withheld; 4,035,425 Broker Non-Votes.
- Proposal 2: Ratification of Independent Auditor
- Ernst & Young LLP was ratified for the fiscal year ending December 31, 2022.
- Votes For: 29,452,775
- Votes Against: 90,096
- Abstentions: 125
- No broker non-votes were recorded for this proposal.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to report the tabulation of stockholder votes.
Key Facts for Investor Verification
- Verify the successful election of the three Class II directors (Woiwode, Beigelman, Hirth) to serve until the 2025 annual meeting.
- Confirm the ratification of Ernst & Young LLP as the independent registered public accounting firm.
- Note the significant number of broker non-votes (4,035,425) recorded for the director election proposal.
- Review the definitive proxy statement on Schedule 14A filed on April 29, 2022, for detailed background on the proposals.